- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Omeros Corporation (OMER)
Omeros Corporation stock price live, this page displays NASDAQ OMER stock exchange data. View the OMER premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Omeros Corporation real time stock price chart below.
What Is the Omeros Corporation Stock Price Today?
The Omeros Corporation stock price today is 4.230.
What Is the Stock Symbol for Omeros Corporation?
The stock symbol for Omeros Corporation is ""OMER.""
What Stock Exchange Does Omeros Corporation Trade On?
Omeros Corporation is listed and trades on the NASDAQ stock exchange.
Is Omeros Corporation a Good Stock to Buy?
Determining whether Omeros Corporation—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the OMER quote. (ISIN: US6821431029)
What Is the Omeros Corporation Stock Price Today?
The Omeros Corporation stock price today is 4.230.
What Is the Stock Symbol for Omeros Corporation?
The stock symbol for Omeros Corporation is ""OMER.""
What Stock Exchange Does Omeros Corporation Trade On?
Omeros Corporation is listed and trades on the NASDAQ stock exchange.
Is Omeros Corporation a Good Stock to Buy?
Determining whether Omeros Corporation—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the OMER quote. (ISIN: US6821431029)
NASDAQ
Currency in USD
Fair Value
An estimate of a Omeros's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
4.185
4.326
52 wk Range
2.950
13.600
OMER Scorecard
Full Analysis
Operates with a significant debt burden
OMER is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a Omeros's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
4.1854.326
52 wk Range
2.95013.600
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
OMER Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a Omeros's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Neutral
Price Target
22.500
Upside
+431.91%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
High shareholder yield
- Form 8K Omeros Corporation For: 25 July
- Investing.com
- Form 8K Omeros Corporation For: 25 July
- Investing.com
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell
Omeros Corporation Company Profile
Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases. The company’s lead products candidate is the Narsoplimab (OMS721/MASP-2) for the treatment of hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); and in Phase II clinical trial to treat COVID-19 and acute respiratory distress syndrome. It also develops OMS1029 that has completed phase I clinical trials for mannan-binding lectin-associated serine protease 2 (MASP-2) and lectin pathway disorders; zaltenibart that is in phase 3 clinical trials for Paroxysmal nocturnal hemoglobinuria; in phase 2 clinical trial for the treatment complement 3 glomerulopathy, and other alternative pathway disorders; and OMS527 that is in phase I clinical trials for addictions and compulsive disorders, and movement disorders, as well as cocaine use disorder. In addition, the company’s products under preclinical development comprise MASP-2, a pro-inflammatory protein target for the treatment of lectin pathway disorders; MASP-3 small-molecule inhibitors for alternative pathway disorders; and Adoptive T-Cell and Immunostimulator Combination Therapies, and Oncotoxins and Immunomodulators for the treatment of various cancers. Omeros Corporation was incorporated in 1994 and is headquartered in Seattle, Washington.
Omeros Corporation Earnings Call Summary for Q2/2025
- Q2 2025 EPS beat forecast with $0.43 loss vs $0.46 expected; stock dipped 0.7% to $4.24 in aftermarket trading
- Net loss reduced to $25.4M from $33.5M in Q1; outstanding principal on 2026 notes cut from $98M to $17M
- Narsoplimab BLA resubmission PDUFA date extended to December 2025; company preparing for launch targeting 175 transplant centers
- Lower Q3 operating expenses projected; interest expenses around $9.2M; exploring asset acquisitions to cover term loan and operational costs
- Analysts cautious due to ongoing regulatory challenges and path to profitability; stock down 53.5% over 6 months despite recent 13% weekly gain
Last Updated: 14/08/2025, 22:32
Read Full TranscriptCompare OMER to Peers and Sector
Metrics to compare | OMER | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipOMERPeersSector | |
|---|---|---|---|---|
P/E Ratio | −2.1x | −0.1x | −0.6x | |
PEG Ratio | −0.23 | 0.21 | 0.00 | |
Price/Book | −1.3x | 1.7x | 2.6x | |
Price / LTM Sales | - | 1.7x | 3.3x | |
Upside (Analyst Target) | - | 94.2% | 39.1% | |
Fair Value Upside | Unlock | 19.3% | 5.4% | Unlock |
Analyst Ratings
2 Buy
2 Hold
0 Sell
Ratings:
4 analysts
Overall Consensus
Buy
Analysts 12-Month Price Target:
Average 22.500
(+431.91% Upside)
Earnings
Latest Release
Aug 14, 2025
EPS / Forecast
-0.43 / -0.46
Revenue / Forecast
28.60M / 416.67K
People Also Watch
FAQ
What Stock Exchange Does Omeros Trade On?
Omeros is listed and trades on the Nasdaq Stock Exchange stock exchange.
What Is the Stock Symbol for Omeros?
The stock symbol for Omeros is "OMER."
What Is the Omeros Market Cap?
As of today, Omeros market cap is 288.22M.
What Is Omeros's Earnings Per Share (TTM)?
The Omeros EPS (TTM) is -2.36.
When Is the Next Omeros Earnings Date?
Omeros will release its next earnings report on 04 Nov 2025.
From a Technical Analysis Perspective, Is OMER a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Neutral.
How Many Times Has Omeros Stock Split?
Omeros has split 0 times.
How Many Employees Does Omeros Have?
Omeros has 202 employees.
What is the current trading status of Omeros (OMER)?
As of 29 Aug 2025, Omeros (OMER) is trading at a price of 4.230, with a previous close of 4.25. The stock has fluctuated within a day range of 4.185 to 4.326, while its 52-week range spans from 2.950 to 13.600.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.